



**CANCER DISCOVERY**  
**VIRTUAL SYMPOSIUM ON**  
**REDUCING THE GLOBAL CANCER BURDEN**

SEPTEMBER 26, 2023

## SPEAKERS



### **Satish Gopal, MD, MPH**

National Cancer Institute/National Institutes of Health

Satish Gopal, MD, MPH, was appointed Director of the Center for Global Health at the National Cancer Institute (NCI) in 2020. In Dr. Gopal's role, he oversees the development of initiatives and collaborations with other NCI and National Institutes of Health partners, NCI-designated cancer centers, and other governmental and non-governmental organizations to support cancer research, promote science-based cancer control, and build research capacity in low- and middle-income countries.



### **Bob T. Li, MD, PhD, MPH**

Memorial Sloan Kettering Cancer Center

Bob T. Li, MD, PhD, MPH, is an Australian medical oncologist at Memorial Sloan Kettering Cancer Center, and Associate Professor at Weill Cornell Medicine, Cornell University, New York. He specializes in precision oncology and has led international clinical trials that resulted in landmark FDA approvals of the first KRAS and HER2 targeted therapies for patients with lung cancer. Dr. Li also serves as Senior Fellow on Public Health at the Asia Society Policy Institute and is founding member of the Bloomberg New Economy International Cancer Coalition and the Cure4Cancer initiative to promote international collaboration in clinical trials.



### **Isabel Mestres, MBA**

City Cancer Challenge

Isabel Mestres, MBA, is the Chief Executive Officer of City Cancer Challenge (C/Can), which has established itself as a leader in building community-led cancer care solutions from the ground up. Dr. Mestres is passionate about evolving public health and finding impactful ways to serve patients in need, she was part of the founding team, and over the last five years has been instrumental in converting more than 70 projects in 13 C/Can cities into engines to accelerate cancer control until now, Dr. Mestres has occupied the post of Director of Global Public Affairs and was part of the founding team. She has also held leadership positions at the International Union for Cancer Control, serving as Director of Membership and Partnership Development, where she developed and implemented an award-winning membership growth strategy and a sustainable, high-value public-private partnership model that resulted in a tenfold increase in corporate, civic, and public sponsorship engagements. Born in Barcelona Spain, Dr. Mestres holds an MBA from ESADE Business School.



### **C. S. Pramesh, MS, FRCS**

Tata Memorial Centre

CS Pramesh, MS, FRCS, is the Director of the Tata Memorial Hospital and the Professor and Head of Thoracic Surgery at the Tata Memorial Centre in Mumbai. Dr. Pramesh serves on the Board of Directors of the Union for International Cancer Control. He is the convener for the National Cancer Grid, a large network of 305 cancer centres in India.



### **Eric Solary, MD**

Gustave Roussy Cancer Center

Eric Solary, MD, is a full-Professor in Hematology at Université Paris-Saclay and a physician scientist in Gustave Roussy Cancer Center (Villejuif, France). Dr. Solary's research focuses on monocyte differentiation and the pathogenesis of chronic myeloid malignancies. He presides over the Coordination and Support Action 4.UNCAN.eu that prepares a European platform to UNDERstand CANcer.

## MODERATORS



### **Lewis C. Cantley, PhD, FAACR**

*CANCER DISCOVERY* Editor-in-Chief

Weill Cornell College of Medicine

Lewis C. Cantley, PhD, FAACR, has made significant advances in cancer research, stemming from his discovery of the signaling pathway phosphoinositide 3-kinase (PI3K) in 1984. His pioneering research has resulted in revolutionary treatments for cancer, diabetes, and autoimmune diseases. The author of over 400 original papers and more than 50 book chapters and review articles, Dr. Cantley is a fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences. He graduated summa cum laude with a B.S. in chemistry from West Virginia Wesleyan College (1971) and obtained a PhD in biophysical chemistry from Cornell University (1975). He conducted postdoctoral research at Harvard University, where he was appointed assistant professor of biochemistry and molecular biology in 1978. He became a professor of physiology at Tufts University in 1985 but returned to Harvard Medical School as professor of cell biology in 1992. He became chief of Harvard's new Division of Signal Transduction, and a founding member of its Department of Systems Biology in 2002. In 2007, he was appointed director of the Beth Israel Deaconess Cancer Center. He joined the faculty of Weill Cornell Medical College and NewYork-Presbyterian Hospital in 2012.



### **Luis A. Diaz Jr, MD, FAACR**

*CANCER DISCOVERY* Editor-in-Chief

Memorial Sloan Kettering Cancer Center

Luis A. Diaz Jr, MD, FAACR, is a leading authority in oncology who has pioneered several genomic diagnostic and therapeutic approaches for cancer. Dr. Diaz is the Head of the Division of Solid Tumor Oncology; Grayer Family Chair, at the Memorial Sloan Kettering Cancer Center where he specializes in the treatment of advanced pancreatic and colorectal cancers and directs the Precision Interception and Prevention Program. He has undergraduate and medical degrees from the University of Michigan and completed residency and medical oncology training at Johns Hopkins. His group was the one of the first to demonstrate that the level of mutations in the circulation, also known as circulating tumor DNA, could be applicable for cancer screening, early detection, monitoring, and measurement of early residual disease after surgery. His team also first conceptualized the use of checkpoint blockade in patients with mismatch repair deficiency. These studies resulted in the first tumor agnostic approval granted by the FDA.